In line with this notion, transgenic expression of Atgl in adipocytes alleviates obesity and metabolic disorders.[2a] Therefore, the adipose Mettl14/m6A pathway may serve as a potential therapeutic target for treatment of obesity and related metabolic disease. Here, METTL14 is linked to obesity due to melanocortin 4 receptor deficiency.